



✉ ask@hllmc.com

📍 8295 N Military Trl
suite k, Palm
Beach Gardens,
FL 33410

🌐 www.hllmc.com

Telephone: (561)842-7422

EDUCATION

Master of Science (*with a concentration in Metabolic and Nutritional Medicine*)

University of South Florida, Morsani College of Medicine

August 8, 2015

Finished first in class

Advanced Fellow in Anti-Aging, Functional, and Regenerative Medicine

American Academy of Anti-Aging Medicine

Certificate # 200704 on December 14, 2007

Board Certified in the Clinical Science of Anti-Aging and Regenerative Medicine

American Board of Anti-Aging and Regenerative Medicine

Certificate # 1560749 issued on November 1, 2007

The specialty recognition identified herein has been received from a private organization not affiliated with or recognized by the Florida Board of Medicine

Preceptorship: Alt Cosmetic Surgery Center, Edina, MN 10/96-8/97

Training in hair transplants and scalp reduction surgery

Mentored by Thomas Alt, MD (past president of the American Board of Cosmetic Surgery)

Dermatology Residency

Medical College of Georgia; Augusta

GA 7/95-7/96

Fellow in Clinical Dermatology Research

University of Miami School of Medicine, Department of Dermatology and Cutaneous

Surgery; Miami, FL 2/94- 5/95

Diplomate, National Board of Medical Examiners 7/93

Central Texas Medical Foundation/ Brackenridge Hospital

Transitional Internship 6/93

Doctor of Medicine, University of Miami School of Medicine,

Miami, FL 5/92



Bachelor of Arts, University of Miami, Coral Gables, FL.

Major in Psychology, Minor in Chemistry 5/82

United States Patent: # 8,889,194, November 18, 2014. Smoking Cessation with Body Weight Maintenance and Nutritional Supplement.

PUBLICATION

A pilot study on the effects of topical antifungal and corticosteroid preparations in an in vitro model of human superficial fungal infection.

Berman B, Bieleley HC, Elgart GW, Frankel SJ, Ramirez CC, Zell D. *Cosmet Dermatol.* April 2005;18(4):291-296

Effects of a water-impermeable, non-silicone based occlusive dressing on keloids.

Bieleley HC, Berman B. *J Am Acad Dermatol* 1996;35(1):113-114

Autosomal dominant pattern of distal subungual onychomycosis caused by *Trichophyton rubrum*.

Zaias N, Tosti A, Rebell G, Morelli R, Bardazzi F, Bieleley H, Zaiac M, Glick B, Payle B, Allevato M, Baran R *J Am Acad Dermatol* 1996; 34(2):302-304

Adjunct therapies to surgical management of keloids.

Berman B, Bieleley HC *Dermatol Surg* 1996;22:126- 130

Keloids.

Berman B, BieleleyHC *J Am Acad Dermatol* 1995;33(1):117-123

Albert's solution versus potassium hydroxide solution in the diagnosis of *Tinea versicolor*.

Payle B, Serrano L, Bieleley HC, Reyes BA. *Int J Dermatol* 1994;33 (3):182-3

The use of Mohs micrographic surgery for determination of residual tumor in incompletely excised basal cell carcinoma.

Bieleley HC, Kirsner RS, Reyes BA, Garland L *J Am Acad Dermatol* 1992;26(5):754-56



**CLINICAL
RESEARCH
PROJECTS**

listed with the Food and Drug Administration (FDA) on Regulatory Form # 1572

**PRINCIPAL
INVESTIGATOR**

This work was done at Palm Beach Research Center, 1897 Palm Beach Lakes Blvd., Suite120, West Palm Beach, FL 33409.

12. A randomized, double blind, clinical trial to evaluate the safety and efficacy of the X for the treatment of androgenetic alopecia in females.
Principal Investigator 8/05

11. A multicenter, open-label, long-term study of X for the treatment of breakthrough pain in opioid - tolerant cancer patients.
Principal Investigator. 6/05

10. A long-term safety and efficacy study of a fixed combination of X 0.1% and Y 2.5% (X and Y topical gel) gel in subjects with acne vulgaris.
Principal Investigator. 1/05

9. A randomized, double blind, parallel group, vehicle-controlled, multiple -dose, combined phase 1/ phase 2 trial of X applied topically to the scalp of subjects with excess sebum.
Principal Investigator 1/05

8. A multicenter, open-label, long-term study of X for the treatment of breakthrough pain in opioid- tolerant cancer patients.
Principal Investigator. 1/05

7. Effect of X in combination with fixed-dose hydrochlorothiazide therapy on systolic blood pressure in hypertensive patients.
Principal Investigator. 10/04

6. An uncontrolled long-term safety trial of X gel, 1% in patients with osteoarthritis of the knee.
Principal Investigator. 10/04



5. Effects of a dietary supplement on osteoarthritis & functional mobility versus glucosamine/chondroitin in a randomized, placebo controlled, double-blind trial.

Principal Investigator. 9/04

4. Evaluation of safety, tolerability, and pharmacokinetics of a 200 µg single dose of X administered buccally to opioid-tolerant cancer patients with or without oral mucositis.

Principal Investigator. 9/04

3. A 12-week, randomized, double blind, multi-center, vehicle-controlled, parallel group study to assess the efficacy and safety of the X Gel 1% for the relief of signs and symptoms in patients with osteoarthritis of the knee.

Principal Investigator. 9/04

2. A randomized, double blind, placebo controlled, parallel design, multi-site, clinical study to evaluate the bioequivalence of two X 0.75% topical gel formulations in patients with moderate to severe rosacea.

Principal Investigator. 6/04

1. A two stage, single-blind, dose-escalating study to assess the efficacy and safety of X gel applied five times per week for up to 12 weeks for the treatment of common warts in adults.

Principal Investigator. 6/04.

SUB INVESTIGATOR

This work was done at Palm Beach Research Center, 1897 Palm Beach Lakes Blvd., Suite120, West Palm Beach, FL 33409.

61. A randomized, double blind, placebo controlled, parallel group, 6-week study of the effect of X aqueous spray 100 mcg qd on the hypothalamic pituitary adrenocortical (HPA) axis in pediatric subjects 2 to <12 years of age with perennial allergic rhinitis (PAR).

Sub-Investigator. 7/05.

60. A randomized, double blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of X 0.5 mg once daily and 0.5 mg twice daily for 12 weeks for the treatment



of opioid-induced bowel dysfunction in adults taking opioid therapy for persistent non-cancer pain.

Sub- Investigator. 7/05

59. A randomized, double blind trial of X 350 mg and 250 mg tablets compared to placebo in patients with acute, painful musculoskeletal spasm of the lower back.

Sub-Investigator. 7/05

58. A randomized, double blind, placebo-controlled study of the safety and efficacy of X extended release (X-ER) tablets in the treatment of patients with postherpetic neuralgia.

Sub-Investigator. 6/05

57. A study of the efficacy and safety of 8 mg X extended-release (X ER) compared to placebo in subjects with persistent pain.

Sub-Investigator. 5/05

56. A randomized, double blind, double-dummy, multicenter, non inferiority phase III study to assess the safety and efficacy of topical 1%X ointment, applied twice daily, versus oral cephalexin, 500 mg in adults, or 12.5 mg/kg (250 mg/5 ml) in children, twice daily, in the treatment of secondarily-infected dermatoses.

Sub-Investigator. 4/05

55. A double blind, placebo-controlled evaluation of the safety and efficacy of three doses of topically applied X Gel in comparison to oral Naproxen for the treatment of the signs and symptoms of osteoarthritis of the knee.

Sub-Investigator. 4/05

54. Two identical, double blind, double-dummy, multicenter, comparative phase III studies of the safety and efficacy of topical 1% X, applied twice daily, versus oral Cephalexin, 500mg in adults, or 12.5mg/kg (250mg/5ml) in children, twice daily, in the treatment of uncomplicated secondary infected traumatic lesions.

Sub-Investigator. 4/05

53. The efficacy of X 3 mg compared to placebo in the treatment of insomnia secondary to perimenopause or menopause.

Sub-Investigator. 3/05



52. A phase III, 12-week, multicentre, double blind, randomized, placebo- and active comparator- controlled, parallel group study to investigate the efficacy and safety of X, 5mg, 10mg, 25mg, and 50mg administered orally once daily, in adults with rheumatoid arthritis.

Sub-Investigator. 3/05

51. Pharmacodynamics of the 88mcg BID dose of the hydrofluoroalkane propellant formulation of inhaled X propionate following administration via the metered dose inhaler in pediatric subjects 4 to 11 years of age with asthma.

Sub-Investigator. 12/04 50.

A multi-center, standard of care-controlled study to evaluate the long-term safety of X for the treatment of chronic low back pain.

Sub-Investigator. 12/04

49. A randomized, double blind, placebo-controlled, parallel-group, 6-week study of the effect of X aqueous nasal spray 100 mcg qd on the hypothalamic pituitary adrenocortical (HPA) axis in pediatric subjects 2 to <12 years of age with perennial allergic rhinitis (PAR).

Sub-Investigator. 12/04

48. A randomized, double blind, double-dummy, multicenter, non inferiority phase III study to assess the safety and efficacy of topical 1% X ointment, applied twice daily, versus oral Cephalexin, 500mg in adults, or 12.5mg/kg (250mg/5mL) in children, twice daily, in the treatment of secondary-infected dermatoses.

Sub-Investigator. 11/04

47. A double blind, randomized, placebo-and active-controlled safety and efficacy study of X/conjugated estrogens combinations in postmenopausal women.

Sub-Investigator. 11/04.

46. A phase 1, double blind, crossover, placebo-controlled, dual injection, safety and pharmacokinetic study of X in patients with diminished DLCO and chronic obstructive pulmonary disease



and/or congestive heart failure.

Sub-Investigator. 11/04

45. A randomized, double blind, placebo-controlled study evaluating X extended-release (3,900 mg/day) in the treatment of osteoarthritis of the hip or knee.

Sub-Investigator. 11/04

44. A randomized, double blind, placebo-controlled multi-center study to assess the efficacy, safety, and tolerability of X alone or in combination with Omeprazole given orally in patients suffering from symptomatic gastroesophageal reflux disease (sGERD).

Sub-Investigator. 11/04

43. A randomized, 24-week, double blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of X (15mg bid) in patients with Chronic Obstructive Pulmonary Disease (COPD).

Sub-Investigator. 10/04

42. A randomized, double blind, active-comparator-controlled, parallel-group study to evaluate the safety of X in patients with osteoarthritis or rheumatoid arthritis.

Sub-Investigator. 10/04

41. A multi-center, double blind, randomized, placebo-controlled study comparing 3 continuous oral X combinations and Y with placebo for a treatment period of 8 weeks on ambulatory and office cuff blood pressure in postmenopausal women with stage 1 or stage 2 essential hypertension.

Sub- Investigator.10/04

40. A 12 month, open-label, multicenter study to evaluate the safety of a 1.3gm oral dose of a new modified- release X acid formulation administered three times daily as needed for up to five days during the menstrual cycle in women with heavy menstrual bleeding associated with menorrhagia.

Sub- Investigator. 10/04

39. A randomized, double blind, parallel design, multi-site clinical study to compare the clinical efficacy and safety of X 0.1% cream with X 0.1% cream in pediatric patients with atopic dermatitis.

Sub- Investigator. 10/04

38. A randomized, double blind, placebo-controlled, parallel group st to evaluate the efficacy and safety of X for the treatment of acute low back pain.

Sub-Investigator. 10/04



37. Efficacy study comparing 0.9 gm and 1.25gm of X 0.03% doses with placebo in the treatment of vasomotor symptoms and vulvar and vaginal atrophy associated with menopause.

Sub-Investigator. 9/04

36. Evaluation of safety and efficacy of of X capsules in induction of secretory conversion of endometrium and withdrawal bleeding in subjects with secondary amenorrhea.

Sub-Investigator. 9/04

35. A randomized, double blind, 6-month evaluation of the safety and efficacy of topical X in hysterectomized women with female sexual arousal disorder (FSAD).

Sub-Investigator. 8/04

34. A randomized, double blind, placebo-controlled, multicenter actual use study of the safety and tolerability of X 250 mg, and 500mg in a potential OTC population.

Sub-Investigator. 8/04

33. A multi-center, double blind, randomized, placebo-controlled study comparing 3 continuous oral X combinations and 17beta-estradiol (1mg) with placebo for a treatment period of 8 weeks on ambulatory and office cuff blood pressure in postmenopausal women with Stage 1 or Stage 2 essential hypertension.

Sub-Investigator. 8/04

32. A long-term, open-label, safety trial of X in patients with fibromyalgia.

Sub-Investigator. 7/04

31. A double blind, randomized, multicenter, two-part, parallel group, dose-ranging study of twice- daily and once-daily X in the treatment of subjects with chronic obstructive pulmonary



disease.

Sub- Investigator. 6/04

30. A multicentre, randomized, double blind, placebo-controlled study of the efficacy and safety of X in patients suffering from functional dyspepsia.

Sub-Investigator. 6/04

29. A multi-center, double blind study to determine the efficacy of X tablets in relieving menopausal symptoms in estrogenized, non-hysterectomized postmenopausal woman.

Sub-Investigator. 6/04 28.

A multi-center, double blind study to determine the efficacy of X tablets in relieving menopausal symptoms in estrogenized, hysterectomized postmenopausal woman.

Sub-Investigator. 6/04

27. A multi-center, double blind study to determine the efficacy of X hs tablets in relieving menopausal symptoms in estrogenized postmenopausal woman.

Sub-Investigator. 6/04

26. A multi-center study to validate the menopausal rating scale (MRS) in a US postmenopausal population.

Sub-Investigator. 6/04

25. Long term safety and efficacy study of a fixed combination of X and Y gel in subjects with acne vulgaris.

Sub-Investigator. 3/04

24. A multicenter, randomized, double blind, active comparison study to determine the efficacy and safety of X20 or Y vs. X5 in subjects with moderate to severe low back pain.

Sub-Investigator. 3/04

23. A randomized, double blind, placebo-controlled, parallel group, multicenter study to determine the efficacy and safety of X transdermal system in subjects with moderate to severe



osteoarthritis pain requiring daily treatment with opioids.

Sub-Investigator. 3/04

22. Study of X in women of different demographic characteristics and comorbidities with stress urinary incontinence: evaluation of efficacy and safety.

Sub-Investigator. 3/04

21. The efficacy of X 3 mg compared to placebo in the treatment of insomnia secondary to perimenopause or menopause.

Sub-Investigator. 3/04

20. Randomized, double blind, placebo-controlled study evaluating X extended release (3,900mg/day) in the treatment of osteoarthritis of the hip or knee.

Sub-Investigator. 3/04

19. A few weeks, randomized, double blind, placebo- and positive-controlled, parallel group, multicenter study of X in subjects with symptomatic osteoarthritis of the knee.

Sub-Investigator. 3/04

18. Efficacy and safety of X in postmenopausal women.

Sub-Investigator.3/04 17. The safety, tolerability and immunogenicity of X vaccine in adults with previous smallpox vaccination.

Sub-Investigator. 3/04

16. The safety, tolerability and immunogenicity of X vaccine in adults without previous smallpox vaccination

Sub-Investigator. 3/04

15. Effects of X on bone mineral density and endometrial histology in postmenopausal women.

Sub-Investigator. 3/04

14. A phase three, parallel group, randomized, double blind, placebo controlled, multicenter trial to investigate the efficacy, tolerability, and safety of X sustained release in subjects with



overactive bladder syndrome.

Sub-Investigator. 3/04

13. A randomized, double blind, placebo controlled, parallel-group, fixed-dose, multicenter study of weight-reducing and prevention of weight regain effects and safety of X in obese patients with or without co-morbidities.

Sub-Investigator. 11/01

12. A phase III, vehicle-controlled study of topical X 0.01% gel applied 2 times per week for 2 weeks each recurrence of anogenital herpes over 12 months.

Sub-Investigator. 10/01

11. A randomized, double blind, multi-center study to assess the safety of the long-term administration of X in patients with primary insomnia.

Sub-Investigator. 10/01

10. A double blind, placebo controlled, multi-center study to assess the effects of extended treatment and re-treatment in patients with plaque psoriasis enrolled in X part2; protocol X.

Sub- Investigator. 9/01

9. A randomized, double blind, placebo-controlled, parallel-group, 12 week trial evaluating the efficacy and safety of the X/Y combination product 250/50mcg once daily versus X/Y Diskus combination product 100/50mcg twice daily, versus X 250/mcg once daily versus placebo in symptomatic adolescent and adult subjects with asthma that is not controlled on short acting beta-2 agonists alone.

Sub- Investigator. 9/01

8. An Evaluation of the ability of X to reduce the daily morphine requirement and limit the escalation of the daily morphine-equivalent dose in order to maintain the same degree of pain control over three months in chronic pain patients with osteoarthritis.

Sub-Investigator. 8/01

7. Open-label Extension of X use in chronic pain patients.



Sub-Investigator. 8/01

6. Evaluation of the efficacy and safety of X CR (X, controlled release relative to Y (Y, controlled release) and placebo in subjects with cancer pain or chronic low back pain.

Sub-Investigator. 8/01

5. A multicenter, randomized, double blind, double dummy, placebo-controlled, complete-block crossover trial assessing the analgesic effects of X in women with primary dysmenorrhea using Y as a comparator.

Sub-Investigator. 8/01

4. A study of the safety and efficacy of X laxative for the treatment of constipation in users of non prescription laxatives.

Sub-Investigator. 8/01

3. A multi-center, randomized, double blind, parallel group, placebo-controlled study to investigate the long-term effects of X/Y propionate 50/500ug bid and X 500ug bid, all delivered via the Discus/Accuhaler™ inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment.

Sub-Investigator. 8/01

2. An open-label pharmacokinetic study of X in Patients with acute bacterial sinusitis, acute exacerbation of chronic bronchitis, *S. pyogenes* tonsillitis/pharyngitis, community acquired pneumonia or uncomplicated skin and skin structure infection.

Sub-Investigator. 8/01

1. Vehicle-controlled, double blind study to assess the safety and efficacy of X 5% cream applied once daily, two days per week for the treatment of actinic keratoses on the head.

Sub-Investigator. 8/01



***Other clinical
research***

at Jackson Memorial
Hospital Medical
Center, Miami, Florida

A randomized prospective study investigating the effectiveness of a biofragmentable anastomosis ring (BAR) versus staples or sutures in colostomy closures.

Trauma service, Dept. of Surgery, University of Miami School of Medicine. Trauma Center, Study done in collaboration with Patricia Byers, M.D., Trauma Services Chief. Sub-Investigator. 1991

Nursing notes study in the surgical intensive care unit (SICU) at Jackson Memorial Hospital, the teaching hospital for the University of Miami School of Medicine.

This study laid the foundation for the first computer system used in the SICU at Jackson Memorial Hospital. Project done in collaboration with Joseph M. Civetta, M.D., Professor of Surgery, Anesthesia, Medicine, and Pathology; Director of all Intensive Care Medicine at Jackson Memorial Hospital in Miami, FL. 1975.

Research Project: Hepatic coma and the sudden death of the alcoholic.

Project done in collaboration with Dade County Medical Examiner, Joseph H. Davis, M.D. 1975.



PRESENTATIONS

Central Savannah River Area Dental Hygiene Society.
5/96. Common Facial Lesions.

In Vitro model of human superficial fungal infection. (Principal Investigator, co-author and poster). American Academy of Dermatology 7/95, Chicago, Illinois; International Summit on cutaneous antifungal therapy, 8/95, New York, New York. ; American Academy of Dermatology, 2/96, Washington, D.C. Berman B, Bieleley HC, Elgart G Oren. Also included in the audiotape, "Highlights of Academy'95, American Academy of Dermatology".

Presentation to the Florida Dermatology Society on Keloids.
Literature review and text notes by Harlan C. Bieleley, M.D. 1994.

Poster- annual meeting of the American Academy of Dermatology 1993, Washington, D.C.: Distal subungual onychomycosis by *T. rubrum* is inherited as an autosomal dominant disease

(Sub- Investigator and co-author).

Continuous spinal anesthesia for major vascular surgery. Southern Society of Anesthesiologists. Basta J, Bieleley HC, Gold MI. 4/78

Clinical Dermatology Research Fellowship,

University of Miami,
School of Medicine,
Department of

Signed Ferndale Labs to a \$21,000 contract to study hypothesis by Sawada and Sone that hydration and occlusion have anti-keloid effects.

Principal Investigator and first author. 2/94

Wrote study protocol and received IRB approval (Univ. of Miami School of Medicine).



Dermatology and
Cutaneous Surgery :

Conducted seminal research using Graftskin (TM), a living skin equivalent , whereby multiple fungal infections were induced then treated with antifungal agents and topical steroids.

Principal Investigator and co- author. 2/94

Wrote study protocol and received IRB approval (Univ. of Miami School of Medicine) to study the effects of pentoxifylline applied to surgical excision sites. Purpose: to determine if topical application of pentoxifylline postoperatively to surgical excision sites effects scar formation, and to determine if topical pentoxifylline improves cosmetic outcome of the scar after surgical revision.

Principal Investigator. 2/94

Received IRB approval (Univ. of Miami School of Medicine) for study protocol to study X cream (X 1% cream) in a double-blind, placebo controlled trial for the treatment of cutaneous candidiasis.

Principal Investigator. 2/94

Wrote study protocol and received IRB approval(University of Miami School of Medicine) A double blind, placebo controlled trial of compound X in the treatment of keloids.

Principal Investigator 3/95

Received IRB approval (Univ. of Miami School of Medicine). The efficacy and safety of X 0.1% with Y cream 0.2% in the treatment of moderate to severe atopic dermatitis.

Principal Investigator. 2/94

Reviewed extensive protocol and prepared cost analysis for a phase III, double-blind, placebo controlled trial for X IL-2, for the treatment of cutaneous T-cell lymphoma (CTCL). Analysis revealed inadequate financial support to cover projected and potential costs and was not undertaken.

Principal Investigator. 2/95



PROFESSIONAL LICENSES

Physician, Florida, # ME0066700

Physician, Tennessee, #MD 2190

Controlled Substance Registration Certificate; DEA Registration,
and NPI (current)

MEMBERSHIPS

International Peptide Society
2018 to present

International Hormone Society
2007 to present

The Institute for Functional Medicine
2006 to present

American Academy of Anti-Aging Medicine
2006 to present

American College of Phlebology
1998- 2007

Canadian Society of Phlebology
1999-2003

American Society of Hair Restoration Surgery
1997-1999



International Society of Hair Restoration Surgery
1998-1999

American Medical Association
1992-2002

Psi Chi, Psychology Honor Society, Univ. of Miami
1992

HONORS

Dean's List: Junior and Senior years
University of Miami

President's Honor Roll: Senior year
University of Miami

PHLEBOLOGY

The American College of Phlebology, 20th Annual Congress, 11/06
Ponte Vedra Beach, Florida.

The American College of Phlebology, 16th Annual Congress, 11/02,
Ft. Lauderdale, Florida.

The American College of Phlebology, 15th Annual Congress, 11/01,
La Quinta, California.



Advances and controversies in the management of venous disorders, Canadian Society of Phlebology, 10/10, Montreal, Canada

Interactive course in phlebology, Canadian Society of Phlebology, 5/00, Dorval (Quebec), Canada.

The American College of Phlebology, 13 Annual Congress, 11/99, Scottsdale, Arizona.

Advances and controversies in management of venous disorders, Canadian Society of Phlebology, 10/99, Montreal, Canada

Update on treatment and management of smaller and larger varicose veins, Canadian Society of Phlebology, 10/00. Montreal, Canada

The American College of Phlebology, 12 Annual Congress, 11/98, San Juan, Puerto Rico

Introduction to Peripheral Vascular Duplex/Color Flow Imaging. Gulfcoast Ultrasound Institute, St. Petersburg, FL. 5/7-8/98

Advanced Course in Phlebology.
Pauline Raymond-Martimbeau Vein Institute, Houston, TX;
conducted by Dr. Martimbeau. 5/16-18/98

Phlebology Skills Transfer Workshop
Pauline Raymond-Martimbeau Vein Institute, Houston, TX;
conducted by Dr. Martimbeau. 11/18-21/97; 1/20-23/98;
5/13-15/98.



**CONTINUING
MEDICAL
EDUCATION
COURSES**

Inflammation: Nutritional Supplement and Hormone Interventions.

May 18, 2023. Orlando, FL

Spring Congress 2023: The Fire Inside- Inflammation the Common Pathway to Disease.

May 19-21, 2023. Orlando, FL

Age Management Medicine Group (AMMG), 32nd Clinical Applications for Age Management Medicine.

Oct 27-30, 2022. Denver, CO.

Peptide Therapy Clinical Training, The Seeds Scientific Research and Performance Institute.

August 12-13, 2022. Ft. Lauderdale, FL

The Great Plains Academy Presents: Beyond the basics: Advanced Organic Acids Testing Strategies.

June 10-12, 2022, live on-line.

Brain Health Summit- Addressing the 4 M's of Brain Aging

November 23, 2021, Virtual

Spring 2021 Mold and Mycotoxins Workshop, The American Academy of Environmental Medicine, Virtual

October 17, 2021

Florida Medical Association: Human Trafficking

November 11, 2020

RTL Workshop Series: Mold Treatment 2020, Virtual

November 7-8, 2020

27th World Congress on Anti-Aging Medicine,

December 13-15, 2019, Las Vegas, NV



**CONTINUING
MEDICAL
EDUCATION
COURSES**

The Next Generation in Hormone Science and Chronic Disease Dr.
Thierry Hertoghe,
December 12, 2019, Las Vegas, NV

2nd Annual Peptide Society Conference, International Peptide Society
August 9-10, 2019, St. Petersburg, FL

International Peptide Society, Mastermind Conference
February 8-9, 2019, Napa Valley California

Guidelines for prescribing controlled substances & addressing opioid
abuse

January 1, 2019

Certification in Peptide Therapy. Peptide Conference. Modules 3 and 4
December 12-15, 2018. Las Vegas, NV

Certification in Peptide Therapy. Peptide Conference. Modules 1 and 2
September 27-29, 2018. Nashville, TN

International Symposium on Fungal Metabolite Treatments 2018
Aug 4-5, 2018, Plano, TX

1 st Annual International Peptide Society Conference. Learn how to
profitably implement peptides into your practice
July 20-21, 2018, Dana Point, CA

Tennessee Guidelines for treatment of Chronic Pain
Dec 2017

Sexual Health Symposium
West Palm Beach, FL Oct 20-21, 2017

SHEICON 2017
Seattle, WA, April 27-30, 2017



**CONTINUING
MEDICAL
EDUCATION
COURSES**

**Breakthroughs in Peptide Therapy: Novel Therapy and
Innovative Uses**

April 6, 2017, Hollywood, FL

Spring Congress 2017

Hollywood, FL, April 7-8, 2017

Metabolic Medical Institute. Advanced Medical Education

Dec 9-11, 2016, Las Vegas, NV

2016 International Summit on Mycotoxin Treatments

June 3-5, 2016. Plano, TX

**Traumatic Brain Injury: A Clinical Approach to Diagnosis and
Treatment**

May 11-12, 2016. Orlando, FL.

The 10 Major Hormone Therapie

November 19, 2015, WOOSAAM, and International Hormone Society
sponsored. Brussels, Belgium

The Aging Head & The Thyroid Symposium

November 20, 2015, WOOSAAM and International Hormone Society
sponsored. Brussels, Belgium

The Aging Female & Male

November 21, 2015, WOOSAAM and International Hormone Society
sponsored. Brussels, Belgium



**CONTINUING
MEDICAL
EDUCATION
COURSES**

Bio-Identical Hormone Replacement Symposium

September 16-19, 2015. New Orleans, LA

The Aging Female: Hormone and Nutritional Therapies

Thierry Hertoghe, MD. September 20, 2015, New Orleans, LA

**Master of Science with a concentration in Metabolic and
Nutritional Medicine. University of South Florida, Morsani
College of Medicine**

August 8, 2015

23rd World Congress on Anti-Aging Medicine

Hollywood, FL. May 8-9, 2015

Institute for Methylation and Bio-individualized Medicine

Philadelphia, PA. January 17-18, 2015.

**22nd Annual World Congress on Anti-Aging and Regenerative
and Aesthetic Medicine**

Orlando, FL. May 17, 2014.

**Domestic Violence and Prevention of Medical Errors. November
8, 2014 • 22nd Annual World Congress on Anti-Aging,
Regenerative & Aesthetic Medicine**

December 11-13, 2014, Las Vegas, NV



**CONTINUING
MEDICAL
EDUCATION
COURSES**

Reverse Physical Aging: Hormone and Nutritional Therapies.

Thierry Hertoghe, MD

December 13-14, 2014. Las Vegas, NV

TN update for physicians. ER/LA Opioid REMS Education. May 20, 2014. • 21st Annual World Congress on Anti-Aging and Regenerative Medicine

Las Vegas, NV, December 12- 15, 2013

Personalized Lifestyle Medicine. Las Vegas, NV. December 12, 2013 • Hormone Therapies in Psychology and Psychiatry

Thierry Hertoghe, MD, Orlando, FL. April 14, 2013

21st Annual World Congress on Anti-Aging and Regenerative Medicine

Orlando, FL. April 11-14, 2013

Helping Our Patients: Useful Diagnostic Observations and Treatments from Forty-Three Years of Medical Practice

Jonathan V. Wright, MD

Orlando, FL. April 11, 2013

Mycotoxins and Chronic Disease

Plano, TX. January 18-19, 2013



**CONTINUING
MEDICAL
EDUCATION
COURSES**

**20th Annual World Congress on Anti-Aging and Regenerative
Medicine**

Las Vegas, NV Dec. 12-15, 2012

**19th Annual International Congress on Anti-Aging Medicine &
Biomedical Technologies**

Dec 7-10, 2011, Las Vegas, NV

The Intensive Clinical Course, PK Protocol

June 24-25, 2011. Millville, NJ

**19th Annual World Congress on Anti-Aging and Aesthetic
Medicine**

April 7-9, 2011, Orlando, FL

**Functional Medicine Updates, CD lectures by Dr. Jeffrey
Bland, Ph.D. 2008 to present.**

**18th Annual International Congress on Anti-Aging Medicine &
Regenerative Biomedical Technologies**

Dec 9-11, 2010, Las Vegas, NV

**18th Annual World Congress on Anti-Aging and Regenerative
Biomedical Technologies**

April 21-25, 2010, Orlando, FL



**CONTINUING
MEDICAL
EDUCATION
COURSES**

**2010 Chronic Illness Seminars. Illuminating the Clinical Web:
Treating Complex Cases**

March 13,2010. Metagenics Educational Program

**17th Annual International Congress on Anti-Aging Medicine &
Regenerative Biomedical Technologies**

Dec 10-12,2009, Las Vegas, NV

**17th Annual World Congress on Anti Aging and-Regenerative
Biomedical Technologies**

April 21-25, 2009, Orlando, FL

**The Future of the Clinic: A Clinician-To-Clinician, Collaborative
Workshop**

February 28,2009. Ft. Lauderdale, FL Metagenics Educational Program.

**16th Annual World Congress on Anti-Aging and Regenerative
Biomedical Technologies**

December 10- 14, 2008, Las Vegas, Nevada

**16th Annual World Congress on Anti-Aging and Regenerative
Biomedical Technologies**

Orlando, FL, April 23-27, 2008

**The Emerging Therapeutic Target: Improving Therapeutic
Outcomes by Treating the Intersection of Osteoporosis,**



**CONTINUING
MEDICAL
EDUCATION
COURSES**

Cardiovascular Disease, Type II Diabetes, and Arthritis

March 29, 2008, Orlando, FL Jeffrey S. Bland, Ph.D., presenter

**The Depression Pandemic: Bridging the Mind-Body Gap by
Balancing the Stress Response**

Jan 26, 2008, Orlando, FL. Jay Lombard, DO, presenter

**15th Annual World Congress on Anti-Aging Medicine and
Regenerative Biomedical Technologies**

December 12-15th, 2007, Las Vegas, Nevada, Winter Session

**The Neurobiology of Mood and Cognitive Disorders. Sept. 16,
2007, Miami, FL. Jay Lombard, DO, presenter.**

**15th Annual World Congress on Anti-Aging Medicine and
Regenerative Biomedical Technologies**

April 23- 28, 2007, Orlando, FL

Applying Functional Medicine in Clinical Practice

November 27- December 2, 2006, Ft. Lauderdale, FL

**American College for Advancement in Medicine (ACAM), Passed
Basic Proficiency in Chelation Therapy (BPCT). Chelation Therapy
Workshop**

Palm Springs, California, November 1-3, 2006

14th International Congress on Anti-Aging Medicine 2006, April



**CONTINUING
MEDICAL
EDUCATION
COURSES**

5-9, 2006, Orlando, FL, and 14 th International Congress on Anti-Aging Medicine, Summer 2006 Session, July 14-16, 2006, I passed the American Academy of Anti-Aging Medicine written and oral board exams, respectively, for Board Certification in Anti-Aging Medicine. The specialty recognition identified herein has been received from a private organization not affiliated with or recognized by the Florida Board of Medicine.

**Integrative Medicine for Anti-Aging™ Conference and
Exposition**

October 21-23, 2005, West Palm Beach, FL

**Botox, Fillers, and More Conference. Vancouver, British
Columbia, Canada**

Hosted by Carruthers group, August 19-20, 2005

**Botox, Fillers, and More Conference. Vancouver, British
Columbia, Canada**

Hosted by Carruthers group, August 20-21, 2004

